Emerald National Laboratory LLC
Emerald National Laboratory LLC was paid $10.15M by Medicaid between Jun 2020 and Dec 2024, across 15 billing codes. Its largest line is G0480, Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed — 61% of everything it billed.
CORVALLIS, OR 97333
Next to other Clinical Medical Laboratory providers in Oregon
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Paid by month
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2020 | 3,757 | $28K | |
| 2021 | 15,829 | $443K | |
| 2022 | 46,898 | $1.94M | |
| 2023 | 60,640 | $3.01M | |
| 2024incomplete | 83,948 | $4.73M |
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | 61% | 101,611 | 45,721 | $6.20M |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 38% | 101,549 | 45,223 | $3.91M |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 2,400 | 689 | $30K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 2,394 | 689 | $10K |
| 80320 | 0% | 287 | 89 | $0.00 | |
| 80359 | 0% | 287 | 89 | $0.00 | |
| 80345 | 0% | 287 | 89 | $0.00 | |
| 80353 | 0% | 287 | 89 | $0.00 | |
| 80358 | 0% | 287 | 89 | $0.00 | |
| 80324 | 0% | 287 | 89 | $0.00 | |
| 80349 | 0% | 287 | 89 | $0.00 | |
| 80346 | 0% | 287 | 89 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.